Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition
NCT ID: NCT00224016
Last Updated: 2012-02-09
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
57 participants
INTERVENTIONAL
2004-12-31
2008-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition
NCT00224029
Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder
NCT00224146
Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder
NCT01192568
Efficacy of Intravesical Oxybutynin in Children With Neurogenic Bladder Dysfunction
NCT07027020
Transdermal Versus Oral Oxybutynin in Pediatric OAB
NCT07081906
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Oxybutynin Transdermal System
Oxybutynin Transdermal System 1.3 mg/day, 2.6 mg/day, or 3.9 mg/day
Oxybutynin
1.3, 2.6, 3.9 mg/day transdermal
Oral oxybutynin
5 to 15 mg/day immediate release or extended release tablets, or syrup
Oxybutynin
5 to 15 mg/day immediate release or extended release tablets, or syrup
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oxybutynin
1.3, 2.6, 3.9 mg/day transdermal
Oxybutynin
5 to 15 mg/day immediate release or extended release tablets, or syrup
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Use clean intermittent catheterization
* On stable dose of oral oxybutynin before participation
Exclusion Criteria
* Have any medical condition that precludes their participation in the study or may confound the outcome of the study
6 Years
15 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Watson Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gary Hoel, RPh, PhD
Role: STUDY_CHAIR
Watson Laboratories, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Watson Investigational Site
Little Rock, Arkansas, United States
Watson Investigational Site
Orange County, California, United States
Watson Investigational Site
San Diego, California, United States
Watson Investigational Site
Denver, Colorado, United States
Watson Investigational Site
Washington D.C., District of Columbia, United States
Watson Investigational Site
Detroit, Michigan, United States
Watson Investigational Site
Minneapolis, Minnesota, United States
Watson Investigational Site
Jackson, Mississippi, United States
Watson Investigational Site
Kansas City, Missouri, United States
Watson Investigational Site
St Louis, Missouri, United States
Watson Investigational Site
Voorhees Township, New Jersey, United States
Watson Investigational Site
Albany, New York, United States
Watson Investigational Site
Buffalo, New York, United States
Watson Investigational Site
Poughkeepsie, New York, United States
Watson Investigational Site
Ashville, North Carolina, United States
Watson Investigational Site
Durham, North Carolina, United States
Watson Investigational Site
Columbus, Ohio, United States
Watson Investigational Site
Oklahoma City, Oklahoma, United States
Watson Investigational Site
Hershy, Pennsylvania, United States
Watson Investigational Site
Dallas, Texas, United States
Watson Investigational Site
Houston, Texas, United States
Watson Investigational Site
Plano, Texas, United States
Watson Investigational Site
Salt Lake City, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Cartwright PC, Coplen DE, Kogan BA, Volinn W, Finan E, Hoel G. Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity. J Urol. 2009 Oct;182(4):1548-54. doi: 10.1016/j.juro.2009.06.058. Epub 2009 Aug 15.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
O03010
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.